2,5-dioxopyrrolidin-1-yl 4-methyl-4-(methyldisulfanyl)pentanoate | 796073-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2,5-dioxopyrrolidin-1-yl 4-methyl-4-(methyldisulfanyl)pentanoate
• 英文别名: (2,5-dioxopyrrolidin-1-yl) 4-methyl-4-(methyldisulfanyl)pentanoate
• CAS: 796073-56-8
• 化学式: C₁₁H₁₇NO₄S₂
• 分子量: 291.392
• InChiKey: UIUQQGXZEMJNCH-UHFFFAOYSA-N

物化性质

• 沸点：
  398.6±44.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,5-dioxopyrrolidin-1-yl 4-methyl-4-(methyldisulfanyl)pentanoate 在 三乙胺 、 N,N'-二环己基碳二亚胺 、 zinc(II) chloride 作用下， 以 乙二醇二甲醚 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 美登素杂质
  参考文献：
  名称：

  Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer

  摘要：

  Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

  DOI：

  10.1021/jm060319f
• 作为产物：
  描述：

  4-mercapto-4-methylvaleronitrile 在 sodium hydroxide 、 sodium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成 2,5-dioxopyrrolidin-1-yl 4-methyl-4-(methyldisulfanyl)pentanoate
  参考文献：
  名称：

  Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer

  摘要：

  Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

  DOI：

  10.1021/jm060319f

文献信息

• [EN] ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES<br/>[FR] CONJUGUÉS D'ANTICORPS COMPRENANT UN AGONISTE DU RÉCEPTEUR DE TYPE TOLL ET POLYTHÉRAPIES
  申请人：NOVARTIS AG

  公开号：WO2018198091A1

  公开（公告）日：2018-11-01

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies. In some embodiments, the conjugates are used in combination with a second therapeutic agent.

  本文提供了包含Toll样受体激动剂的抗体偶联物，以及利用这些偶联物治疗癌症的用途。在某些实施例中，这些偶联物包括抗HER2抗体。在某些实施例中，这些偶联物与第二治疗剂联合使用。
• [EN] DC-SIGN ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉ MÉDICAMENT-ANTICORPS ANTI-DC-SIGN
  申请人：NOVARTIS AG

  公开号：WO2020089811A1

  公开（公告）日：2020-05-07

  Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.

  本文提供了针对DC-SIGN的抗体，DC-SIGN抗体的结合物，以及DC-SIGN抗体融合蛋白，以及利用这些抗体、结合物和融合蛋白治疗癌症等疾病的用途。
• [EN] ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST<br/>[FR] CONJUGUÉS D'ANTICORPS COMPRENANT UN AGONISTE DU RÉCEPTEUR DE TYPE TOLL
  申请人：NOVARTIS AG

  公开号：WO2017072662A1

  公开（公告）日：2017-05-04

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

  本文提供了包含Toll样受体激动剂的抗体偶联物，以及利用这些偶联物治疗癌症的用途。在某些实施例中，这些偶联物包括抗HER2抗体。
• NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：BOUCHARD Hervé

  公开号：US20120225089A1

  公开（公告）日：2012-09-06

  Provided herein are cryptophycin conjugates and compositions containing them. Methods of making and using such compounds also are provided.

  本发明提供了隐藻素偶联物及其包含它们的组合物。还提供了制备和使用此类化合物的方法。
• Cytotoxic agents comprising new maytansinoids
  申请人：IMMUNOGEN, INC.

  公开号：US20040235840A1

  公开（公告）日：2004-11-25

  New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the &agr;-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

  揭示了具有α-碳原子上带有硫原子的单烷基或双烷基取代基的新硫醇和二硫化物含有马坦西诺伊德。还公开了合成这些新马坦西诺伊德的方法以及将这些新马坦西诺伊德连接到细胞结合剂的方法。马坦西诺伊德-细胞结合剂结合物可用作治疗剂，专门传递到靶细胞并具有细胞毒性。与先前描述的药物相比，这些结合物在动物肿瘤模型中显示出大大改善的治疗效果。